Complete switch to darbepoetin in a hemodialysis unit

Area of Science:

• Nephrology
• Pharmacoeconomics

Background:

• Erythropoiesis-stimulating agents (ESAs) are crucial for managing anemia in hemodialysis patients.
• Subcutaneous recombinant human erythropoietin (rHuEPO) has been a standard treatment.
• Intravenous darbepoetin offers a potentially more convenient and cost-effective alternative.

Purpose of the Study:

• To compare the efficacy of intravenous (i.v.) darbepoetin versus subcutaneous (s.c.) rHuEPO in maintaining target hemoglobin (Hb) levels.
• To evaluate the manufacturer's recommended dosing guidelines for converting from rHuEPO to darbepoetin.
• To assess the cost implications of switching to darbepoetin therapy in a hemodialysis unit.

Main Methods:

• An 18-month, open-label observational study involving 95 hemodialysis patients.
• Retrospective data collection for six months pre-switch (rHuEPO phase) and prospective data for 12 months post-switch (darbepoetin phase).
• Hb levels were monitored, and doses were titrated to a target of 120-135 g/l, with the initial six months of darbepoetin considered a dose titration period.

Main Results:

• No significant difference in mean Hb levels was observed between the rHuEPO and darbepoetin phases.
• Median darbepoetin dose remained stable at 30 microg/week, while rHuEPO dose increased.
• Estimated 12-month cost savings of $212,000 with darbepoetin, though manufacturer conversion guidelines were insufficient for high-dose rHuEPO patients.

Conclusions:

• Intravenous darbepoetin is effective in maintaining serum Hb levels comparable to subcutaneous rHuEPO in hemodialysis patients.
• Switching to darbepoetin therapy resulted in substantial cost reductions.
• A simplified dose conversion nomogram is proposed for more accurate darbepoetin dosing.